2019 American Transplant Congress
Breakthrough Changes in the Access to Transplantation for the Patients with Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
On behalf of the French aHUS Study Group, France, France
*Purpose: Eculizumab has revolutionized the management of atypical Hemolytic Uremic Syndrome (aHUS). In 2012, the French aHUS Study Group issued recommendations to advocate a pro-transplantation…2019 American Transplant Congress
Atypical Hemolytic Uremic Syndrome Concomitant Complement Factor H Gene Variations Leading to Early Renal Allograft Loss: Multicenter Cases Report from China
*Purpose: The ratio of early renal allograft loss caused by hyperacute rejection, severe surgical complications and sever infection decreased gradually during recent years. Atypical hemolytic…2019 American Transplant Congress
Prophylactic Use of Eculizumab in Patients at High Risk of Post-Transplant aHUS Recurrence Improves Graft Outcomes
On behalf of the French aHUS Group, France, France
*Purpose: Eculizumab has revolutionized the management of atypical Hemolytic Uremic Syndrome (aHUS). In 2012, the French aHUS Study Group issued recommendations to advocate the prophylactic…2019 American Transplant Congress
Eculizumab in Kidney Transplant Recipients with Atypical Hemolytic Uremic Syndrome – Single Center Experience
Division of Transplant Nephrology, Johns Hopkins Hospital, Baltimore, MD
*Purpose: Atypical hemolytic uremic syndrome (aHUS) is caused by genetic mutations of components of the alternative complement pathway in 60-70% of cases; and has a…2018 American Transplant Congress
Thrombotic Microangiopathy after Renal Transplantation: A Clinicopathological Study and Identification of Prognostic Factors
IntroductionThrombotic microangiopathy (TMA), whether de novo or recurrent, is a serious complication after renal transplantation, but prognostic factors and the role of complement inhibitors in…2018 American Transplant Congress
The Promising Approach in Difficult Atypical Hemolytic Uremic Syndrome Series in Renal Transplantation
BACKGROUND:Atypical hemolytic-uremic syndrome (aHUS) belongs to the group of thrombotic microangiopathies (TMAs), which can recur after renal transplantation if they have been identified as the…2017 American Transplant Congress
Eculizumab Dose Reduction Is Safe by Monitoring Eculizumab Pre-Dose Level and Functional Complement Assays.
Background & aims: Untreated atypical haemolytic syndrome (aHUS) leads to ESRD and may recur after renal transplantation. Eculizumab (Ecu), a humanized antibody inhibiting terminal C5…2016 American Transplant Congress
Renal Outcome with Eculizumab in Patients with aHUS with Native and Transplanted Kidneys: Pooled Analysis of 100 Patients.
Purpose: aHUS often progresses to ESRD and requires transplant (tx). Eculiumab (ECU), a terminal complement inhibitor, inhibits TMA irrespective of tx status. We evaluated outcomes…2016 American Transplant Congress
Early Post Renal Transplant aHUS in Patients with Heterozygous CFHR3-CFHR1 Deletion.
Renal Division, Washington University, Saint Louis, MO.
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare disease with a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Subjects homozygous for…2016 American Transplant Congress
Successful Prophylactic Use of Eculizumab in aHUS Kidney Transplant Patients: A Report of 9 Cases.
AHUS is a thrombotic microangiopathy (TMA) triggered by alternate complement pathway (AP) dysregulation. In 60% of patients, a pathogenic variant can be identified in one…
American Transplant Congress abstracts